Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropinirole add-on to sertraline for major depressive disorder
IRCT20090117001556N171Phase 3Recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ropinirole in major depressive disorder (MDD) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Depression severity. Started Sep 2026; status: recruiting.
02
Drugs
ropinirole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20090117001556N171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090117001556N171.